FULVESTRANT
Resistant to (Neo)Adjuvant Endocrine Therapy
Fudan UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Resistant to (Neo)Adjuvant Endocrine Therapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ganetespib Synta Pharmaceuticals Corp. | Phase 2 | CCC |
Cyclophosphamide Leap Therapeutics, Inc. | Phase 1 | CC |
trx518 Leap Therapeutics, Inc. | Phase 1 | CC |
ag-01 compound A&G Pharmaceutical Inc. | Phase 1 | CC |
Avelumab Leap Therapeutics, Inc. | Phase 1 | CC |
Palbociclib Fudan University | N/A | D |
Rapamycin Fudan University | N/A | D |
Same molecule, other indications
FULVESTRANT is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →